TGX تصريحات هيئة الأوراق المالية والبورصات - Theragenics Corp- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

CIK

795551

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Theragenics Corp

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

February 10, 2014	SC 13G/A	TGX / Theragenics Corp / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* THERAGENICS CORP (Name of Issuer) Common Stock (Title of Class of Securities) 883375107 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
November 12, 2013	15-12G	- FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-14339 Theragenics Corporation® (Exact name of registrant as specified in
November 6, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As Filed with the Securities and Exchange Commission on November 6, 2013. Registration No. 333-136640 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 THERAGENICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1528626 (State or other jurisdiction
November 6, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As Filed with the Securities and Exchange Commission on November 6, 2013. Registration No. 333-40653 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 THERAGENICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1528626 (State or other jurisdiction
November 6, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As Filed with the Securities and Exchange Commission on November 6, 2013. Registration No. 333-48136 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 THERAGENICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1528626 (State or other jurisdiction
November 6, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As Filed with the Securities and Exchange Commission on November 6, 2013. Registration No. 333-15313 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 THERAGENICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1528626 (State or other jurisdiction
November 6, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As Filed with the Securities and Exchange Commission on November 6, 2013. Registration No. 333-165503 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ——————— THERAGENICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1528626 (State or ot
November 6, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As Filed with the Securities and Exchange Commission on November 6, 2013. Registration No. 333-181573 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ——————— THERAGENICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1528626 (State or ot
November 4, 2013	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION THERAGENICS CORPORATION ARTICLE I The name of the corporation is Theragenics Corporation (the “Corporation”). ARTICLE II Registered Office and Registered Agent EXHIBIT 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THERAGENICS CORPORATION ARTICLE I Name The name of the corporation is Theragenics Corporation (the “Corporation”). ARTICLE II Registered Office and Registered Agent The address of the registered office of the Corporation in the State of Delaware is Corporation Service Company, 2711 Centerville Road, Suite 400, in the City of Wilmingt
November 4, 2013	EX-3.2	AMENDED AND RESTATED THERAGENICS CORPORATION Table of Contents Section Page Article I OFFICES SECTION 1.01. Registered Office 1 SECTION 1.02. Other Offices 1 Article II MEETINGS OF STOCKHOLDERS SECTION 2.01. Annual Meetings 1 SECTION 2.02. Special Me EXHIBIT 3.2 AMENDED AND RESTATED BY-LAWS OF THERAGENICS CORPORATION Table of Contents Section Page Article I OFFICES SECTION 1.01. Registered Office 1 SECTION 1.02. Other Offices 1 Article II MEETINGS OF STOCKHOLDERS SECTION 2.01. Annual Meetings 1 SECTION 2.02. Special Meetings 1 SECTION 2.03. Notice of Meetings 2 SECTION 2.04. Waiver of Notice 2 SECTION 2.05. Adjournments 2 SECTION 2.06. Quorum
November 4, 2013	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Emplo
October 31, 2013	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Registration No. 333-127551 Registration No. 333-143839 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENTS File Numbers 333-127551 and 333-143839 UNDER THE SECURITIES ACT OF 1933 ——————— THERAGENICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1528626 (State or other ju
October 31, 2013	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Registration No. 333-127551 Registration No. 333-143839 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENTS File Numbers 333-127551 and 333-143839 UNDER THE SECURITIES ACT OF 1933 ——————— THERAGENICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1528626 (State or other ju
October 30, 2013	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on November 12, 2013, pursuant to the provisions of Rule 12d2-2 (a).
October 22, 2013	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Emplo
October 7, 2013	DEFA14A	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employ
October 7, 2013	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employ
September 17, 2013	DEFM14A	- DEFINITIVE PROXY STATEMENT TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
September 9, 2013	DEFA14A	- SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use
August 23, 2013	PREM14A	- PRELIMINARY PROXY STATEMENT TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
August 13, 2013	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORATION®
August 13, 2013	DEFA14A	- SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use
August 12, 2013	EX-99.B	INTERIM INVESTORS AGREEMENT EX-99.B 3 d582521dex99b.htm EX-99.B Exhibit B INTERIM INVESTORS AGREEMENT THIS INTERIM INVESTORS AGREEMENT (this “Agreement”) is made as of August 2, 2013, by and among Juniper Acquisition Corporation, a Delaware corporation (“MergerCo”), Juniper Investment Company, LLC, a Delaware limited liability company (“Juniper”), Juniper TGX Investment Partners, LLC, a Delaware limited liability company (“E
August 12, 2013	SC 13D	TGX / Theragenics Corp / GMMF Equity Holdings LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Theragenics Corporation (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 883375107 (CUSIP Number) Julian Weldon Garrison Investment Group LP 1350 Avenue of the Americas New York, NY 10019 (212) 372-9500 (Name, Address and Telephone Nu
August 12, 2013	EX-99.A	ESCROW AGREEMENT EX-99.A Exhibit A ESCROW AGREEMENT ESCROW AGREEMENT (as may be amended, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), dated as of August 2, 2013 by and among Juniper Investment Company, LLC, a Delaware limited liability company (“Juniper”), Fifth Third Capital Holdings, LLC, a Delaware limited liability company (“Fifth Third”, and, together with Jun
August 12, 2013	SC 13D	TGX / Theragenics Corp / Fifth Third Capital Holdings, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Theragenics Corporation (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 883375107 (CUSIP Number) Richard W. Holmes, Jr. Fifth Third Bank 38 Fountain Square Plaza, MD 10AT76 Cincinnati, Ohio 45263 (513) 534-6030 (Name, Address and Tele
August 8, 2013	DEFA14A	- THERAGENICS CORPORATION 8-K DEFA14A 1 a50687380.htm THERAGENICS CORPORATION 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: August 8, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Nu
August 8, 2013	EX-99.1	Theragenics Corporation Reports Second Quarter 2013 Results EX-99.1 2 a50687380ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theragenics Corporation Reports Second Quarter 2013 Results BUFORD, Ga.-(BUSINESS WIRE)-August 8, 2013-Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended June 30, 2013. Consolidated Resul
August 8, 2013	EX-99.1	Theragenics Corporation Reports Second Quarter 2013 Results Exhibit 99.1 Theragenics Corporation Reports Second Quarter 2013 Results BUFORD, Ga.-(BUSINESS WIRE)-August 8, 2013-Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended June 30, 2013. Consolidated Results Revenue $20.3 million in Q2 2013, down 8
August 8, 2013	8-K	Results of Operations and Financial Condition - THERAGENICS CORPORATION 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: August 8, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bristol
August 7, 2013	DEFA14A	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employe
August 7, 2013	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employe
August 7, 2013	EX-99.1	August 2, 2013 Exhibit 99.1 August 2, 2013 Theragenics Corporation 5203 Bristol Industrial Way Buford, Georgia 30518 Ladies and Gentlemen: This Letter Agreement is being delivered by Juniper TGX Investment Partners, LLC (the “Investor”) to Theragenics Corporation, a Delaware corporation (the “Company”), in connection with the execution of that Agreement and Plan of Merger, dated as of the date hereof (as it may
August 7, 2013	EX-2.1	AGREEMENT AND PLAN OF MERGER by and between JUNIPER ACQUISITION CORPORATION THERAGENICS CORPORATION Dated as of August 2, 2013 TABLE OF CONTENTS Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and between JUNIPER ACQUISITION CORPORATION and THERAGENICS CORPORATION Dated as of August 2, 2013 TABLE OF CONTENTS Page ARTICLE I THE MERGER Section 1.1 The Merger 1 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effects of the Merger 2 Section 1.5 Organizational Documents 2 Section 1.6 Directors and Officers of Surviv
August 7, 2013	EX-10.1	FIRST AMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT FIRST AMENDMENT, dated as of August 2, 2013 (this “Amendment”), to the Amended and Restated Rights Agreement, dated as of February 14, 2007 (the “Rights Agreement”), between Theragenics Corporation, a Delaware corporation (the “Company”) and Computershare Trust Company, N.A., a federally chartered trust company, successor rights
August 7, 2013	EX-10.1	FIRST AMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT FIRST AMENDMENT, dated as of August 2, 2013 (this “Amendment”), to the Amended and Restated Rights Agreement, dated as of February 14, 2007 (the “Rights Agreement”), between Theragenics Corporation, a Delaware corporation (the “Company”) and Computershare Trust Company, N.A., a federally chartered trust company, successor rights
August 7, 2013	EX-99.2	Juniper to Acquire Theragenics Corporation Stockholders to Receive $2.20 per share in Cash EX-99.2 5 ex99-2.htm EXHIBIT 99.2 Exhbit 99.2 Company Contacts: Frank Tarallo, CFO & Treasurer or Lisa Rassel, Manager of Investor Relations Phone: 800-998-8479 - 770-271-0233 Website: www.theragenics.com Juniper to Acquire Theragenics Corporation Stockholders to Receive $2.20 per share in Cash BUFORD, GA, August 5, 2013 – Theragenics Corporation® (NYSE: TGX) (the “Company”), a medical device comp
August 7, 2013	EX-99.2	Juniper to Acquire Theragenics Corporation Stockholders to Receive $2.20 per share in Cash Exhbit 99.2 Company Contacts: Frank Tarallo, CFO & Treasurer or Lisa Rassel, Manager of Investor Relations Phone: 800-998-8479 - 770-271-0233 Website: www.theragenics.com Juniper to Acquire Theragenics Corporation Stockholders to Receive $2.20 per share in Cash BUFORD, GA, August 5, 2013 – Theragenics Corporation® (NYSE: TGX) (the “Company”), a medical device company serving the surgical products
August 7, 2013	EX-99.1	August 2, 2013 Exhibit 99.1 August 2, 2013 Theragenics Corporation 5203 Bristol Industrial Way Buford, Georgia 30518 Ladies and Gentlemen: This Letter Agreement is being delivered by Juniper TGX Investment Partners, LLC (the “Investor”) to Theragenics Corporation, a Delaware corporation (the “Company”), in connection with the execution of that Agreement and Plan of Merger, dated as of the date hereof (as it may
August 7, 2013	EX-2.1	AGREEMENT AND PLAN OF MERGER by and between JUNIPER ACQUISITION CORPORATION THERAGENICS CORPORATION Dated as of August 2, 2013 TABLE OF CONTENTS EX-2.1 2 ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and between JUNIPER ACQUISITION CORPORATION and THERAGENICS CORPORATION Dated as of August 2, 2013 TABLE OF CONTENTS Page ARTICLE I THE MERGER Section 1.1 The Merger 1 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effects of the Merger 2 Section 1.5 Organizational Documents 2 Section 1.6 D
August 5, 2013	EX-99.J	Patrick Sullivan 151 Plympton Road Sudbury, MA 01776 EX-99.J 6 ss183592ex99j.htm EQUITY COMMITMENT LETTER Exhibit J Patrick Sullivan 151 Plympton Road Sudbury, MA 01776 August 2, 2013 Juniper TGX Investment Partners, LLC c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Patrick Sullivan (the “Investor”) is pleased to offer his commitment in connection with that certain Agreement and Plan of M
August 5, 2013	EX-99.O	Exhibt O Exhibt O THERAGENICS CORPORATION® Company Contacts: Frank Tarallo, CFO & Treasurer or Lisa Rassel, Manager of Investor Relations Phone: 800-998-8479 - 770-271-0233 Website: www.
August 5, 2013	EX-99.M	CREDIT SUISSE SECURITIES (USA) LLC Eleven Madison Avenue New York, NY 10010 GARRISON INVESTMENT GROUP LP 1350 Avenue of the Americas New York, NY 10019 CREDIT SUISSE AG Eleven Madison Avenue New York, NY 10010 Exhibit M CREDIT SUISSE SECURITIES (USA) LLC Eleven Madison Avenue New York, NY 10010 GARRISON INVESTMENT GROUP LP 1350 Avenue of the Americas New York, NY 10019 CREDIT SUISSE AG Eleven Madison Avenue New York, NY 10010 CONFIDENTIAL August 2, 2013 Juniper Holdings, Inc.
August 5, 2013	EX-99.L	Juniper Public Fund, L.P. c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 EX-99.L 8 ss183592ex99l.htm ROLLOVER EQUITY COMMITMENT LETTER Exhibit L Juniper Public Fund, L.P. c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 August 2, 2013 Juniper TGX Investment Partners, LLC c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Juniper Public Fund, L.P. (the “Investor”) is pleased to
August 5, 2013	EX-99.N	August 2, 2013 Exhibit N August 2, 2013 Theragenics Corporation 5203 Bristol Industrial Way Buford, Georgia 30518 Ladies and Gentlemen: This Letter Agreement is being delivered by Juniper TGX Investment Partners, LLC (the “Investor”) to Theragenics Corporation, a Delaware corporation (the “Company”), in connection with the execution of that Agreement and Plan of Merger, dated as of the date hereof (as it may be amended from time to time, the “Merger Agreement”), between Juniper Acquisition Corporation, a Delaware corporation (“MergerCo”) and the Company, pursuant to which MergerCo will merge with and into the Company.
August 5, 2013	EX-99.R	AMENDED AND RESTATED JOINT FILING AGREEMENT EXHIBIT R AMENDED AND RESTATED JOINT FILING AGREEMENT This Amended and Restated Joint Filing Agreement (this “Agreement”), dated as of August 5, 2013, is made by and among Juniper Public Fund, L.
August 5, 2013	EX-99.G	Garrison Capital Equity Holdings LLC 1350 Avenue of the Americas New York, NY 10019 EX-99.G 3 ss183592ex99g.htm EQUITY COMMITMENT LETTER Exhibit G Garrison Capital Equity Holdings LLC 1350 Avenue of the Americas New York, NY 10019 August 2, 2013 Juniper TGX Investment Partners, LLC c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Garrison Capital Equity Holdings LLC (the “Investor”) is pleased to offer its commitment in c
August 5, 2013	SC 13D/A	TGX / Theragenics Corp / MICHAS ALEXIS P - AMENDMENT NO. 4 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Theragenics Corporation (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 883375107 (CUSIP Number) Alexis P. Michas Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, New York 10022 (212) 339-858
August 5, 2013	EX-99.P	AGREEMENT AND PLAN OF MERGER by and between JUNIPER ACQUISITION CORPORATION THERAGENICS CORPORATION Dated as of August 2, 2013 TABLE OF CONTENTS Exhibit P AGREEMENT AND PLAN OF MERGER by and between JUNIPER ACQUISITION CORPORATION and THERAGENICS CORPORATION Dated as of August 2, 2013 TABLE OF CONTENTS Page ARTICLE I THE MERGER Section 1.
August 5, 2013	EX-99.F	Juniper TGX Investors, LLC c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 Exhibit F Juniper TGX Investors, LLC c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 August 2, 2013 Juniper TGX Investment Partners, LLC c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Juniper TGX Investors, LLC (the “Investor”) is pleased to offer its commitment in connection with that certain Agreement and Plan of Merger, dated as of the date hereof (as amended from time to time, the “Merger Agreement”), between Juniper Acquisition Corporation, a Delaware corporation (“Buyer”), and Theragenics Corporation, a Delaware corporation (the “Company”).
August 5, 2013	EX-99.I	Bradford Koenig 3500 Alamedade Las Pulgas, Suite 200 Menlo Park, CA 94025 Exhibit I Bradford Koenig 3500 Alamedade Las Pulgas, Suite 200 Menlo Park, CA 94025 August 2, 2013 Juniper TGX Investment Partners, LLC c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Bradford Koenig (the “Investor”) is pleased to offer his commitment in connection with that certain Agreement and Plan of Merger, dated as of the date hereof (as amended from time to time, the “Merger Agreement”), between Juniper Acquisition Corporation, a Delaware corporation (“Buyer”), and Theragenics Corporation, a Delaware corporation (the “Company”).
August 5, 2013	EX-99.Q	INTERIM INVESTORS AGREEMENT Exhibit Q INTERIM INVESTORS AGREEMENT THIS INTERIM INVESTORS AGREEMENT (this “Agreement”) is made as of August 2, 2013, by and among Juniper Acquisition Corporation, a Delaware corporation (“MergerCo”), Juniper Investment Company, LLC, a Delaware limited liability company (“Juniper”), Juniper TGX Investment Partners, LLC, a Delaware limited liability company (“Equity LLC”), and the individuals and entities set forth on Schedule I attached hereto (such individuals and entities being, the “Equity Investors” and, together with Juniper, the “Investors”).
August 5, 2013	EX-99.K	James Grant 125 East 72nd Street New York, NY 10021 EX-99.K 7 ss183592ex99k.htm EQUITY COMMITMENT LETTER Exhibit K James Grant 125 East 72nd Street New York, NY 10021 August 2, 2013 Juniper TGX Investment Partners, LLC c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: James Grant (the “Investor”) is pleased to offer his commitment in connection with that certain Agreement and Plan of Merger,
August 5, 2013	DEFA14A	- SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use
August 5, 2013	EX-99.H	GMMF Equity Holdings LLC 1350 Avenue of the Americas New York, NY 10019 EX-99.H 4 ss183592ex99h.htm EQUITY COMMITMENT LETTER Exhibit H GMMF Equity Holdings LLC 1350 Avenue of the Americas New York, NY 10019 August 2, 2013 Juniper TGX Investment Partners, LLC c/o Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: GMMF Equity Holdings LLC (the “Investor”) is pleased to offer its commitment in connection with that cert
June 13, 2013	EX-99.2	Juniper Investment Company, LLC 600 Madison Avenue New York, New York 10022 212 339 8500 EXHIBIT 99.2 Juniper Investment Company, LLC 600 Madison Avenue New York, New York 10022 212 339 8500 CONFIDENTIAL June 12, 2013 Members of the Board of Directors Theragenics Corporation 5203 Bristol Industrial Way Buford, Georgia 30518 Dear Members of the Board of Directors, Reference is made to our letter dated May 12, 2013, (the “May Letter”) expressing our interest in acquiring Theragenics Cor
June 13, 2013	EX-99.1	Theragenics Corporation Extends Exclusivity Period Under Letter Agreement with Juniper Investment Company Juniper Affirms $2.25-$2.30 Per Share Proposal EX-99.1 2 ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Theragenics Corporation Extends Exclusivity Period Under Letter Agreement with Juniper Investment Company Juniper Affirms $2.25-$2.30 Per Share Proposal BUFORD, GA, June 13, 2013 – Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that, based on ongoing d
June 13, 2013	EX-99.E	[Balance of page intentionally blank] Juniper Investment Company, LLC JUNIPER INVESTMENT COMPANY 600 Madison Avenue New York, New York 10022 212 339 8500 CONFIDENTIAL June 12, 2013 Members of the Board of Directors Theragenics Corporation 5203 Bristol Industrial Way Buford, Georgia 30518 Dear Members of the Board of Directors, Reference is made to our letter dated May 12, 2013, (the “May Letter”) expressing our interest in acquiring Theragenics Corporation (“Theragenics” or the “Company”).
June 13, 2013	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer
June 13, 2013	SC 13D/A	TGX / Theragenics Corp / MICHAS ALEXIS P - AMENDMENT NO. 3 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Theragenics Corporation (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 883375107 (CUSIP Number) Alexis P. Michas Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, New York 10022 (212) 339-858
May 21, 2013	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001 - 14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employe
May 13, 2013	SC 13D/A	TGX / Theragenics Corp / MICHAS ALEXIS P - AMENDMENT NO. 2 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Theragenics Corporation (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 883375107 (CUSIP Number) Alexis P. Michas Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, New York 10022 (212) 339-858
May 13, 2013	8-K	Financial Statements and Exhibits, Other Events - THERAGENICS CORPORATION 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer
May 13, 2013	EX-99.2	May 12, 2013 Exhibit 99.2 Juniper Investment Company, LLC 600 Madison Avenue New York, New York 10022 JUNIPER INVESTMENT COMPANY CONFIDENTIAL May 12, 2013 Members of the Board of Directors Theragenics Corporation Attention: M. Christine Jacobs Chairman and Chief Executive Officer 5203 Bristol Industrial Way Buford, Georgia 30518 Dear Ms. Jacobs and Members of the Board of Directors, Ι wanted to provide you wit
May 13, 2013	10-Q	UNITED STATES 10-Q 1 t7641510q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001
May 13, 2013	EX-99.C	2 Juniper Investment Company, LLC JUNIPER INVESTMENT COMPANY 600 Madison Avenue New York, New York 10022 212 339 8500 CONFIDENTIAL May 10, 2013 Members of the Board of Directors Theragenics Corporation Attention: M.
May 13, 2013	EX-99.1	Theragenics Corporation Receives Proposal to Acquire all Outstanding Common Stock at $2.25 to $2.30 Per Share Exhibit 99.1 Theragenics Corporation Receives Proposal to Acquire all Outstanding Common Stock at $2.25 to $2.30 Per Share BUFORD, Ga.-(BUSINESS WIRE)-May 13, 2013-Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that its Board of Directors has received a proposal from Juniper Investment Company, LLC
May 13, 2013	EX-99.D	2 Juniper Investment Company, LLC JUNIPER INVESTMENT COMPANY 600 Madison Avenue New York, New York 10022 212 339 8500 CONFIDENTIAL May 12, 2013 Members of the Board of Directors Theragenics Corporation Attention: M.
May 9, 2013	EX-99.1	Theragenics Corporation Reports First Quarter 2013 Results Announces Restructuring of Vascular Access Manufacturing Expected Annual Savings of $3.3 to $3.6 million When Completed Exhibit 99.1 Theragenics Corporation Reports First Quarter 2013 Results Announces Restructuring of Vascular Access Manufacturing Expected Annual Savings of $3.3 to $3.6 million When Completed BUFORD, Ga.-(BUSINESS WIRE)-May 9, 2013-Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financi
May 9, 2013	8-K	Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition - THERAGENICS CORPORATION 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer I
April 1, 2013	DEF 14A	- SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 8, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2012 o TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14339 THERAGENICS CORPORATION® (Exa
March 8, 2013	EX-10.31	THERAGENICS CORPORATION RESTRICTED STOCK AWARD Exhibit 10.31 THERAGENICS CORPORATION RESTRICTED STOCK AWARD THIS AGREEMENT (sometimes referred to as this ?Award?) is made as of the Grant Date, by Theragenics Corporation (the ?Company?) to (the ?Recipient?). Upon and subject to the Terms and Conditions attached hereto and incorporated herein by reference as part of this Agreement, the Company hereby awards as of the Grant Date to the Recipient
February 27, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001 - 14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Em
February 14, 2013	EX-99.1	Theragenics Reports Fourth Quarter and Year-End 2012 Results Exhibit 99.1 Theragenics Reports Fourth Quarter and Year-End 2012 Results BUFORD, Ga.-(BUSINESS WIRE)-February 14, 2013-Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2012. Consolidated Results Consolidated revenue $1
February 14, 2013	8-K	Results of Operations and Financial Condition - THERAGENICS CORPORATION 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: February 14, 2013 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bris
February 11, 2013	SC 13G/A	TGX / Theragenics Corp / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* THERAGENICS CORP (Name of Issuer) Common Stock (Title of Class of Securities) 883375107 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
November 13, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORAT
November 13, 2012	EX-10.2	ATTACHMENT A TO ADVISOR TO THE CHIEF EXECUTIVE OFFICER AGREEMENT JOHN V. HERNDON AND THERAGENICS CORPORATION Exhibit 10.2 September 5, 2012 Mr. John V. Herndon Dear John, This letter agreement confirms your continued employment by Theragenics Corporation (the “Company”) effective September 5, 2012 (the “Effective Date”), as an Advisor to the Chief Executive Officer. This letter supersedes and replaces the letter agreement dated February 3, 2011. In this role, you will advise the CEO and management on mat
November 8, 2012	EX-99.1	Theragenics Reports Revenue and Earnings for Third Quarter 2012 Exhibit 99.1 Theragenics Reports Revenue and Earnings for Third Quarter 2012 BUFORD, Ga.-(BUSINESS WIRE)-November 8, 2012-Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the third quarter ended September 30, 2012. Consolidated Results and Highlights Consolidated re
November 8, 2012	8-K	Results of Operations and Financial Condition - THERAGENICS CORP. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: November 8, 2012 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Brist
October 16, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): (October 10, 2012) THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000 - 15443 58-1528626 (State of incorporation) (Commission File Number) (IRS E
October 16, 2012	EX-10.1	SECOND AMENDED AND RESTATED CREDIT AGREEMENT DATED AS OF OCTOBER 10, 2012 THERAGENICS CORPORATION, C.P. MEDICAL CORPORATION, GALT MEDICAL CORP. and NEEDLETECH PRODUCTS, INC., as Borrowers, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Bank EXHIBIT 10.1 SECOND AMENDED AND RESTATED CREDIT AGREEMENT DATED AS OF OCTOBER 10, 2012 AMONG THERAGENICS CORPORATION, C.P. MEDICAL CORPORATION, GALT MEDICAL CORP. and NEEDLETECH PRODUCTS, INC., as Borrowers, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Bank Article I 1 1. DEFINITIONS 1 1.1 Defined Terms 1 1.2 Accounting Terms 25 1.3 UCC Terms 26 1.4 Construction of Terms 26 1.5 Computation of Ti
August 13, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORATION®
August 9, 2012	EX-99.1	Theragenics Reports Revenue and Earnings for the Second Quarter and First Half of 2012 Highest Quarterly and First Half Revenue Ever Exhibit 99.1 Theragenics Reports Revenue and Earnings for the Second Quarter and First Half of 2012 Highest Quarterly and First Half Revenue Ever BUFORD, Ga.-(BUSINESS WIRE)-August 9, 2012-Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended Jun
August 9, 2012	8-K	Results of Operations and Financial Condition - THERAGENICS CORPORATION 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: August 9, 2012 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bristol
July 18, 2012	EX-99.(A)(5)(E)	Theragenics Announces Final Results of Dutch Auction Tender Offer Exhibit (a)(5)(E) Company Contacts: Frank Tarallo, CFO & Treasurer or Lisa Rassel, Manager of Investor Relations Phone: 800-998-8479 - 770-271-0233 Website: www.
July 18, 2012	SC 13D/A	TGX / Theragenics Corp / MICHAS ALEXIS P - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment SC 13D/A 1 ss149349sc13da.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Theragenics Corporation (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 883375107 (CUSIP Number) Alexis P. Michas Juniper Investment Company, LLC 600 Mad
July 18, 2012	SC TO-I/A	- SCHEDULE TO (AMENDMENT NO. 3) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934. (Amendment No. 3) THERAGENICS CORPORATION® (Name of Filing Persons (Issuer and Offeror)) Common Stock, $0.01 par value (Title of Class of Securities) 883375107 (CUSIP Number of Class of Securities) M. Ch
July 12, 2012	EX-99.(A)(5)(D)	Theragenics Announces Preliminary Results of Dutch Auction Tender Offer EX-99.(A)(5)(D) 2 ex99-a5d.htm EXHIBIT (A)(5)(D) Exhibit (a)(5)(D) THERAGENICS CORPORATION® Company Contacts: Frank Tarallo, CFO & Treasurer or Lisa Rassel, Manager of Investor Relations Phone: 800-998-8479 - 770-271-0233 Website: www.theragenics.com Theragenics Announces Preliminary Results of Dutch Auction Tender Offer BUFORD, GA. — July 12, 2012 — Theragenics Corporation® (NYSE: TGX), a medical
July 12, 2012	SC TO-I/A	- SCHEDULE TO (AMENDMENT NO. 2) SC TO-I/A 1 t74087sctoia.htm SCHEDULE TO (AMENDMENT NO. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934. (Amendment No. 2) THERAGENICS CORPORATION® (Name of Filing Persons (Issuer and Offeror)) Common Stock, $0.01 par value (Title of Class of Securi
June 22, 2012	SC TO-I/A	- SCHEDULE TO (AMENDMENT NO. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934. (Amendment No. 1) THERAGENICS CORPORATION® (Name of Filing Persons (Issuer and Offeror)) Common Stock, $0.01 par value (Title of Class of Securities) 883375107 (CUSIP Number of Class of Securities) M. Ch
June 12, 2012	EX-99.(A)(1)(C)	THERAGENICS CORPORATION® NOTICE OF GUARANTEED DELIVERY FOR TENDER OF SHARES OF COMMON STOCK Exhibit (a)(1)(C) THERAGENICS CORPORATION® NOTICE OF GUARANTEED DELIVERY FOR TENDER OF SHARES OF COMMON STOCK As set forth in Section 3 of the Offer to Purchase (as defined below), this Notice of Guaranteed Delivery, or one substantially in the form hereof, must be used to accept the Offer (as defined below) by Theragenics Corporation if: ● certificates evidencing shares of Theragenics Corporation common stock, $0.
June 12, 2012	EX-99.2	THERAGENICS CORPORATION® Company Contacts: Frank Tarallo, CFO & Treasurer or Lisa Rassel, Manager of Investor Relations Phone: 800-998-8479 - 770-271-0233 Website: www.theragenics.com Exhibit 99.2 THERAGENICS CORPORATION® Company Contacts: Frank Tarallo, CFO & Treasurer or Lisa Rassel, Manager of Investor Relations Phone: 800-998-8479 - 770-271-0233 Website: www.theragenics.com Theragenics® Announces Plans to Repurchase up to $10 Million of its Shares in a Modified Dutch Auction Tender Offer BUFORD, Ga. — (BUSINESS WIRE) — June 12, 2012 — Theragenics Corporation® (NYSE: TGX), a
June 12, 2012	EX-10.1	THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT EXHIBIT 10.1 THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this "Amendment") is dated as of June 11, 2012, among (i) THERAGENICS CORPORATION, C.P. MEDICAL CORPORATION, GALT MEDICAL CORP. and NEEDLETECH PRODUCTS, INC. (each a "Borrower" and collectively the "Borrowers"), and (ii) WELLS FARGO BANK, NATIONAL ASSOCIATION, succes
June 12, 2012	EX-99.(A)(1)(A)	OFFER TO PURCHASE FOR CASH SHARES OF ITS COMMON STOCK FOR AN AGGREGATE PURCHASE PRICE OF $10 MILLION AT A PURCHASE PRICE NOT LESS THAN $2.00 PER SHARE NOR GREATER THAN $2.40 PER SHARE IN A MODIFIED DUTCH AUCTION THE OFFER AND WITHDRAWAL RIGHTS EXPIRE Exhibit (a)(1)(A) OFFER TO PURCHASE FOR CASH SHARES OF ITS COMMON STOCK FOR AN AGGREGATE PURCHASE PRICE OF $10 MILLION AT A PURCHASE PRICE NOT LESS THAN $2.
June 12, 2012	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2012 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001 - 14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employ
June 12, 2012	EX-99.(A)(5)(A)	THERAGENICS CORPORATION® Company Contacts: Frank Tarallo, CFO & Treasurer or Lisa Rassel, Manager of Investor Relations Phone: 800-998-8479 - 770-271-0233 Website: www.theragenics.com Exhibit (a)(5)(A) THERAGENICS CORPORATION® Company Contacts: Frank Tarallo, CFO & Treasurer or Lisa Rassel, Manager of Investor Relations Phone: 800-998-8479 - 770-271-0233 Website: www.
June 12, 2012	EX-99.1	MEMORANDUM Exhibit 99.1 MEMORANDUM To: Executive Officers and Directors of Theragenics Corporation From: M. Christine Jacobs Date: June 12, 2012 Re: Notice of Blackout Period Reason for the Blackout Period and this Notice In connection with our tender offer to repurchase up to $10 million of our common stock, the Theragenics Corporation Employee Savings Plan (the “401(k) Plan”) will be required to impose a b
June 12, 2012	EX-99.(A)(1)(E)	THERAGENICS CORPORATION® OFFER TO PURCHASE FOR CASH SHARES OF ITS COMMON STOCK FOR AN AGGREGATE PURCHASE PRICE OF $10 MILLION AT A PURCHASE PRICE NOT LESS THAN $2.00 PER SHARE NOR GREATER THAN $2.40 PER SHARE IN A MODIFIED DUTCH AUCTION Exhibit (a)(1)(E) THERAGENICS CORPORATION® OFFER TO PURCHASE FOR CASH SHARES OF ITS COMMON STOCK FOR AN AGGREGATE PURCHASE PRICE OF $10 MILLION AT A PURCHASE PRICE NOT LESS THAN $2.
June 12, 2012	EX-99.(A)(1)(B)	LETTER OF TRANSMITTAL TO ACCOMPANY SHARES OF COMMON STOCK OF THERAGENICS CORPORATION TENDERED PURSUANT TO THE OFFER TO PURCHASE DATED JUNE 12, 2012 THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 5:00 P.M., NEW YORK TIME, ON JULY 11, 2012, UNLESS THE OFFER EX-99.(A)(1)(B) 3 ex99-a1b.htm EXHIBIT (A)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL TO ACCOMPANY SHARES OF COMMON STOCK OF THERAGENICS CORPORATION TENDERED PURSUANT TO THE OFFER TO PURCHASE DATED JUNE 12, 2012 THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 5:00 P.M., NEW YORK TIME, ON JULY 11, 2012, UNLESS THE OFFER IS EXTENDED YOU SHOULD CAREFULLY READ THIS LETTER OF TRANSMITTAL, INCLUDING THE AC
June 12, 2012	SC TO-I	- SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934. THERAGENICS CORPORATION® (Name Of Subject Company (Issuer)) THERAGENICS CORPORATION® (Name of Filing Persons (Issuer and Offeror)) Common Stock, $0.01 par value (Title of Class of Securities) 883375107 (
June 12, 2012	EX-99.(A)(5)(B)	M E M O R A N D U M Exhibit (a)(5)(B) M E M O R A N D U M To: All Theragenics Employees From: M. Christine Jacobs Date: June 12, 2012 Re: Theragenics Stock Repurchase Good Morning: You may have seen our press release this morning announcing our plans to repurchase up to $10 million of our own common stock in a “Modified Dutch Auction” tender offer. I realize that you probably have several questions about this auction
June 12, 2012	EX-99.(A)(1)(D)	THERAGENICS CORPORATION® OFFER TO PURCHASE FOR CASH SHARES OF ITS COMMON STOCK FOR AN AGGREGATE PURCHASE PRICE OF $10 MILLION AT A PURCHASE PRICE NOT LESS THAN $2.00 PER SHARE NOR GREATER THAN $2.40 PER SHARE IN A MODIFIED DUTCH AUCTION EX-99.(A)(1)(D) 5 ex99-a1d.htm EXHIBIT (A)(1)(D) Exhibit (a)(1)(D) THERAGENICS CORPORATION® OFFER TO PURCHASE FOR CASH SHARES OF ITS COMMON STOCK FOR AN AGGREGATE PURCHASE PRICE OF $10 MILLION AT A PURCHASE PRICE NOT LESS THAN $2.00 PER SHARE NOR GREATER THAN $2.40 PER SHARE IN A MODIFIED DUTCH AUCTION THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 5:00 P.M., NEW YORK TIME, ON JULY 11, 2012, UNLESS THE
June 12, 2012	EX-99.(A)(1)(F)	IMMEDIATE ATTENTION REQUIRED Exhibit (a)(1)(F) IMMEDIATE ATTENTION REQUIRED June 12, 2012 RE: Theragenics Corporation Employee Savings Plan Theragenics Corporation Tender Offer Dear Participant or Beneficiary: The enclosed tender offer materials and Direction Form require your immediate attention.
May 22, 2012	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints M.
May 22, 2012	S-8	- FORM S-8 As filed with the Securities and Exchange Commission on May 22, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 21, 2012	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2012 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001 - 14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employe
May 14, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORATION®
May 14, 2012	EX-2.1	ASSET PURCHASE AGREEMENT by and between THERAGENICS CORPORATION, CORE ONCOLOGY, INC. Dated as of February 17, 2012 TABLE OF CONTENTS Exhibit 2.1 ASSET PURCHASE AGREEMENT by and between THERAGENICS CORPORATION, and CORE ONCOLOGY, INC. Dated as of February 17, 2012 TABLE OF CONTENTS Page 1. DEFINITIONS 1 1.1. Definitions 1 1.2. Usage 2 2. PURCHASE AND SALE OF ASSETS AND ASSIGNMENT AND ASSUMPTION OF LIABILITIES 2 2.1. Purchase and Sale of Acquired Assets; Assumption of Assumed Liabilities 2 2.2. Purchase Price 3 2.3. Manner of Pay
May 10, 2012	EX-99.1	Theragenics® Reports Revenue & Earnings for First Quarter 2012 Highest Quarterly Revenue Ever Revenue up 7% and Net Earnings Doubles vs. 2011 Exhibit 99.1 Theragenics® Reports Revenue & Earnings for First Quarter 2012 Highest Quarterly Revenue Ever Revenue up 7% and Net Earnings Doubles vs. 2011 BUFORD, Ga.-(BUSINESS WIRE)-May 10, 2012-Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ende
May 10, 2012	8-K	Results of Operations and Financial Condition - THERAGENICS CORP. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: May 10, 2012 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bristol I
May 7, 2012	EX-10.1	NON-COMPETITION, NON-SOLICITATION AND CONFIDENTIALITY AGREEMENT Exhibit 10.1 NON-COMPETITION, NON-SOLICITATION AND CONFIDENTIALITY AGREEMENT This Non-Competition, Non-Solicitation and Confidentiality Agreement (the “Agreement”) is made as of the day of , 2012 by and between Theragenics Corporation, a Delaware corporation (the “Company”), and , an employee of the Company (the “Employee”). WHEREAS, the Company Group wishes to protect and maintain its confidentia
May 7, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2012 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer I
April 4, 2012	DEF 14A	- SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 6, 2012	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2011 o TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14339 THERAGENICS CORPORATION® (Exa
March 5, 2012	SC 13D	TGX / Theragenics Corp / MICHAS ALEXIS P - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Theragenics Corporation (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 883375107 (CUSIP Number) Alexis P. Michas Juniper Investment Company, LLC 600 Madison Avenue, 16th Floor New York, New York 10022 (212) 339-8585
March 1, 2012	EX-10.1	THERAGENICS CORPORATION 2012 OMNIBUS INCENTIVE PLAN THERAGENICS CORPORATION 2012 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS Page SECTION I. DEFINITIONS 1 1.1 Definitions 1 SECTION 2 THE OMNIBUS INCENTIVE PLAN 6 2.1 Purpose of the Plan 6 2.2 Stock Subje EXHIBIT 10.1 THERAGENICS CORPORATION 2012 OMNIBUS INCENTIVE PLAN THERAGENICS CORPORATION 2012 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS Page SECTION I. DEFINITIONS 1 1.1 Definitions 1 SECTION 2 THE OMNIBUS INCENTIVE PLAN 6 2.1 Purpose of the Plan 6 2.2 Stock Subject to the Plan 7 2.3 Administration of the Plan 7 2.4 Eligibility and Limits 8 SECTION 3 TERMS OF AWARDS 8 3.1 Terms and Conditions of Al
March 1, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2012 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer
February 24, 2012	8-K	Entry into a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2012 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001 - 14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Em
February 23, 2012	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: February 23, 2012 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bris
February 23, 2012	EX-99.1	Theragenics® Reports Revenue & Earnings for Fourth Quarter & Year-End 2011 Acquisition of Core Oncology Customer Base Expands Brachy Market Presence Exhibit 99.1 Theragenics® Reports Revenue & Earnings for Fourth Quarter & Year-End 2011 Acquisition of Core Oncology Customer Base Expands Brachy Market Presence BUFORD, Ga.-(BUSINESS WIRE)-February 23, 2012-Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth
February 14, 2012	SC 13G/A	TGX / Theragenics Corp / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* THERAGENICS CORP (Name of Issuer) Common Stock (Title of Class of Securities) 883375107 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
February 14, 2012	SC 13G/A	TGX / Theragenics Corp / CONUS PARTNERS INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 10, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORAT
November 3, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: November 3, 2011 THERAGENICS CORPORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: November 3, 2011 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Brist
November 3, 2011	EX-99.1	Theragenics Reports Revenue and Earnings for Third Quarter 2011 Third Quarter EPS Increases to $0.03 in 2011 from $0.02 in 2010 Year-to-Date EPS Increases to $0.08 from $0.05 in 2010 Exhibit 99.1 Theragenics Reports Revenue and Earnings for Third Quarter 2011 Third Quarter EPS Increases to $0.03 in 2011 from $0.02 in 2010 Year-to-Date EPS Increases to $0.08 from $0.05 in 2010 BUFORD, Ga.-(BUSINESS WIRE)-November 3, 2011-Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidate
September 14, 2011	EX-3.1	AMENDED AND RESTATED BY-LAWS THERAGENICS CORPORATION (A DELAWARE CORPORATION) As Adopted September 8, 2011 ARTICLE I EXHIBIT 3.1 AMENDED AND RESTATED BY-LAWS OF THERAGENICS CORPORATION (A DELAWARE CORPORATION) As Adopted September 8, 2011 ARTICLE I STOCKHOLDERS Section 1.1 CERTIFICATES REPRESENTING STOCK. (a) The shares of stock of the corporation may be issued in book-entry form or evidenced by certificates. However, every stockholder of stock in the corporation shall be entitled upon request to have a certific
September 14, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2011 THERAGENICS COR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2011 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001 - 14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Em
August 11, 2011	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORATION?
August 11, 2011	EX-99.1	Theragenics Reports Record Revenue for Second Quarter and First Half of 2011 Second Quarter EPS of $0.04 in 2011 vs. $0.02 in 2010 Exhibit 99.1 Theragenics Reports Record Revenue for Second Quarter and First Half of 2011 Second Quarter EPS of $0.04 in 2011 vs. $0.02 in 2010 BUFORD, Ga.-(BUSINESS WIRE)-August 11, 2011-Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended June
August 11, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: August 11, 2011 THERAGENICS CORPORATI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: August 11, 2011 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bristo
May 24, 2011	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY BE IT KNOWN, that I, Peter A. A. Saunders, the undersigned, do herby grant a power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation?, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: (1) Sign and file reports on Securities and Exchange Commission Forms 3,4,5 and 144 w
May 24, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2011 THERAGENICS CORPORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2011 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer
May 24, 2011	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, Kathleen A. Dahlberg, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following o
May 24, 2011	EX-24	POWER OF ATTORNEY Power of Attorney for Charles D. Moody, Jr. POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lynn Rogers, Assistant Secretary of Theragenics Corporation® with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Secur
May 24, 2011	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, Kathleen A. Dahlberg, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following o
May 24, 2011	EX-24	POWER OF ATTORNEY POA POWER OF ATTORNEY BE IT KNOWN, that I, John V. Herndon, the undersigned, do herby grant a power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: (1) Sign and file reports on Securities and Exchange Commission Forms 3,4,5 and 144 wi
May 24, 2011	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, K. Wyatt Engwall, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my
May 12, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORATION®
May 5, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: May 5, 2011 THERAGENICS CORPORATION® UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: May 5, 2011 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bristol In
May 5, 2011	EX-99.1	Theragenics Reports Revenue & Earnings for First Quarter 2011 Exhibit 99.1 Theragenics Reports Revenue & Earnings for First Quarter 2011 BUFORD, Ga.-(BUSINESS WIRE)-May 5, 2011-Theragenics Corporation? (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2011. Highlights Consolidated revenue of $20.3 million in the first
April 18, 2011	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e
April 1, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___) Filed by the Registrant x Filed by a Party other tha UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 3, 2011	EX-24	LIMITED POWER OF ATTORNEY LIMITED POWER OF ATTORNEY BE IT KNOWN, that I, Bruce W. Smith, the undersigned, do hereby grant a limited power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation?, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: 1. Sign and file reports on Securities and Exchange Commission Forms 3, 4,
March 3, 2011	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Francis J.
March 1, 2011	EX-24	POWER OF ATTORNEY Power of Attorney for M Lang POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Francis J.
March 1, 2011	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, Janet Zeman, the undersigned, do herby grant a power of attorney to Francis J.
March 1, 2011	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2011 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Empl
March 1, 2011	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, C. Russell Small, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my
March 1, 2011	EX-24	LIMITED POWER OF ATTORNEY LIMITED POWER OF ATTORNEY BE IT KNOWN, that I, M. Christine Jacobs, the undersigned, do hereby grant a limited power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation?, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: 1. Sign and file reports on Securities and Exchange Commission Forms
March 1, 2011	EX-24	POWER OF ATTORNEY Power of Attorney for Frank Tarallo POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lynn Rogers, Assistant Secretary of Theragenics Corporation® with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
March 1, 2011	EX-24	LIMITED POWER OF ATTORNEY LIMITED POWER OF ATTORNEY BE IT KNOWN, that I, Bruce W. Smith, the undersigned, do hereby grant a limited power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation?, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: 1. Sign and file reports on Securities and Exchange Commission Forms 3, 4,
February 25, 2011	EX-10.31	EMPLOYMENT AGREEMENT EXHIBIT 10.31 EMPLOYMENT AGREEMENT This employment agreement (the ?Employment Agreement?) is made as of the 6th day of January, 2011, between THERAGENICS CORPORATION, a Delaware Corporation (the ?Company?), and Joseph Plante (the ?Employee?). INTRODUCTION The Company and the Employee desire to enter into an employment agreement setting forth the terms and conditions of the Employee?s employment. N
February 25, 2011	EX-10.12	ATTACHMENT A TO ADVISOR TO THE CHIEF EXECUTIVE OFFICER AGREEMENT BETWEEN JOHN V. HERNDON AND THERAGENICS CORPORATION Exhibit 10.12 February 3, 2011 Mr. John V. Herndon Dear John, This letter confirms your continued employment by Theragenics Corporation (the “Company”) effective February 18, 2011 (the “Effective Date”), as an Advisor to the Chief Executive Officer. In this role, you will advise the CEO and management on matters of strategy or other areas that the Company may request. You will not have a specific
February 25, 2011	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2010 o TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14339 THERAGENICS CORPORATION® (Exa
February 15, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: February 15, 2011 THERAGENICS CORPORA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: February 15, 2011 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bris
February 15, 2011	EX-99.1	Theragenics® Reports Highest Annual Revenue in its History 2010 REVENUE GROWS 11% IN THE FOURTH QUARTER AND 5% FOR THE YEAR Exhibit 99.1 Theragenics? Reports Highest Annual Revenue in its History 2010 REVENUE GROWS 11% IN THE FOURTH QUARTER AND 5% FOR THE YEAR BUFORD, Ga.-(BUSINESS WIRE)-February 15, 2011-Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets,, today announced consolidated financial results for the fourth quarter and year ended
February 14, 2011	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Theragenics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 883375107 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 11, 2011	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* OMB APPROVAL OMB Number: 3235-0287 Expires: February 28, 2011 Estimated average burden hours per response………11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 11, 2011	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* THERAGENICS CORP (Name of Issuer) Common Stock (Title of Class of Securities) 883375107 (CUSIP Number) D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* THERAGENICS CORP (Name of Issuer) Common Stock (Title of Class of Securities) 883375107 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
February 1, 2011	EX-99.1	Theragenics Corporation to Suspend Shipments of TheraSeed® to Core Oncology, Inc. Theragenics Also Provides Notice of Termination of Supply Agreement Exhibit 99.1 Theragenics Corporation to Suspend Shipments of TheraSeed® to Core Oncology, Inc. Theragenics Also Provides Notice of Termination of Supply Agreement BUFORD, Ga.-(BUSINESS WIRE)-February 1, 2011-Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced it is suspending shipments of TheraSeed® pall
February 1, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): Feb UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2011 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Emplo
November 12, 2010	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORAT
November 9, 2010	EX-99.1	Theragenics® Reports Revenue & Earnings for Third Quarter 2010 Third Quarter Consolidated Revenue 6% over 2009 Organic Revenue Growth in both Surgical Products & Brachytherapy Segments Exhibit 99.1 Theragenics® Reports Revenue & Earnings for Third Quarter 2010 Third Quarter Consolidated Revenue 6% over 2009 Organic Revenue Growth in both Surgical Products & Brachytherapy Segments BUFORD, Ga.-(BUSINESS WIRE)-November 9, 2010-Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidat
November 9, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: November 9, 2010 THERAGENICS CORPORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: November 9, 2010 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Brist
August 12, 2010	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORATION®
August 10, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: August 10, 2010 THERAGENICS CORPORATI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: August 10, 2010 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bristo
August 10, 2010	EX-99.1	Theragenics Reports Revenue & Earnings for Second Quarter 2010 Company Reports Highest Quarterly and Six Month Revenue Ever Exhibit 99.1 Theragenics Reports Revenue & Earnings for Second Quarter 2010 Company Reports Highest Quarterly and Six Month Revenue Ever BUFORD, Ga.-(BUSINESS WIRE)-August 10, 2010-Theragenics Corporation? (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended June 30, 20
August 6, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2010 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001 - 14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Emplo
August 6, 2010	EX-10.1	FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this "Amendment") is dated as of August 4, 2010, and effective as of June 30, 2010, among (i) THERAGENICS CORPORATION, C.P. MEDICAL CORPORATION, GALT MEDICAL CORP. and NEEDLETECH PRODUCTS, INC. (each a "Borrower" and collectively the "Borrowers"), and (ii) WELLS FARG
June 4, 2010	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, K. Wyatt Engwall, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my
June 3, 2010	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, K. Wyatt Engwall, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my
May 20, 2010	EX-24	POWER OF ATTORNEY POA FOR PAAS POWER OF ATTORNEY BE IT KNOWN, that I, Peter A. A. Saunders, the undersigned, do herby grant a power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: (1) Sign and file reports on Securities and Exchange Commission Forms 3,
May 14, 2010	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, Kathleen A. Dahlberg, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following o
May 14, 2010	EX-24	POWER OF ATTORNEY POA POWER OF ATTORNEY BE IT KNOWN, that I, John V. Herndon, the undersigned, do herby grant a power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: (1) Sign and file reports on Securities and Exchange Commission Forms 3,4,5 and 144 wi
May 14, 2010	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, K. Wyatt Engwall, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my
May 14, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORAT
May 14, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2010 THERAGENICS CORPORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2010 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001 - 14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employe
May 14, 2010	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lynn Rogers, Assistant Secretary of Theragenics Corporation? with full power of substitution, the undersigned?s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
May 14, 2010	EX-24	POWER OF ATTORNEY POA FOR PAAS POWER OF ATTORNEY BE IT KNOWN, that I, Peter A. A. Saunders, the undersigned, do herby grant a power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: (1) Sign and file reports on Securities and Exchange Commission Forms 3,
May 4, 2010	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: May 4, 2010 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bristol In
May 4, 2010	EX-99.1	Theragenics Reports Revenue & Earnings for First Quarter 2010 $20.3 Million is Highest Quarterly Revenue Ever Organic Revenue Growth of 11% in Surgical Products Segment Exhibit 99.1 Theragenics Reports Revenue & Earnings for First Quarter 2010 $20.3 Million is Highest Quarterly Revenue Ever Organic Revenue Growth of 11% in Surgical Products Segment BUFORD, Ga.-(BUSINESS WIRE)-May 4, 2010-Theragenics Corporation? (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results
April 6, 2010	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___) Filed by the Registrant x Filed by a Party other tha UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 16, 2010	S-8	As filed with the Securities and Exchange Commission on March 16, 2010 As filed with the Securities and Exchange Commission on March 16, 2010 Registration No.
March 16, 2010	EX-10.1	THERAGENICS CORPORATION EMPLOYEE STOCK PURCHASE PLAN Exhibit 10.1 THERAGENICS CORPORATION EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Theragenics Corporation Employee Stock Purchase Plan (the “Plan”) is to provide employees of Theragenics Corporation (the “Company”) and its Subsidiaries (as defined herein) with an opportunity to be compensated through the benefits of stock ownership and to acquire an interest in the Company through t
March 15, 2010	EX-10.31	THERAGENICS CORPORATION CASH INCENTIVE PLAN SECTION I. INTRODUCTION EXHIBIT 10.31 THERAGENICS CORPORATION CASH INCENTIVE PLAN SECTION I. INTRODUCTION 1.1 Purpose. The purpose of the Theragenics Corporation Cash Incentive Plan (the “Plan”) is to provide cash incentive compensation to certain employees of Theragenics Corporation (the “Company”) and its Affiliates to stimulate their efforts to attain certain operational, strategic and other goals established by the C
March 15, 2010	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2009 o TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001 - 14339 THERAGENICS CORPORATION® (E
March 3, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2010 (February 25, 2010) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2010 (February 25, 2010) THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-14339 58-1528626 (State of incorporation) (Commission File N
March 1, 2010	EX-24	POWER OF ATTORNEY Power of Attorney for Frank Tarallo POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lynn Rogers, Assistant Secretary of Theragenics Corporation® with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
March 1, 2010	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, C. Russell Small, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my
March 1, 2010	EX-24	POWER OF ATTORNEY Power of Attorney for M Lang POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Francis J.
March 1, 2010	EX-24	LIMITED POWER OF ATTORNEY poa LIMITED POWER OF ATTORNEY BE IT KNOWN, that I, Bruce W. Smith, the undersigned, do hereby grant a limited power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: 1. Sign and file reports on Securities and Exchange Commission Forms 3
March 1, 2010	EX-24	LIMITED POWER OF ATTORNEY poa LIMITED POWER OF ATTORNEY BE IT KNOWN, that I, M. Christine Jacobs, the undersigned, do hereby grant a limited power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: 1. Sign and file reports on Securities and Exchange Commission Fo
March 1, 2010	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, Janet Zeman, the undersigned, do herby grant a power of attorney to Francis J.
February 22, 2010	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, K. Wyatt Engwall, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my
February 16, 2010	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.__2__)* OMB APPROVAL OMB Number: 3235-0287 Expires: February 28, 2011 Estimated average burden hours per response………11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 12, 2010	SC 13G	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Theragenics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 883375107 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 11, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: February 11, 2010 THERAGENICS CORPORA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: February 11, 2010 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bris
February 11, 2010	EX-99.1	Theragenics® Reports Record Revenue with 2009 Results $78.3 Million is Highest Annual Revenue in 29-Year History Pro forma Organic Growth of 10% in Surgical Products Segment for 2009 Supply and Reseller Agreement with Core Oncology adds to Momentum f Exhibit 99.1 Theragenics? Reports Record Revenue with 2009 Results $78.3 Million is Highest Annual Revenue in 29-Year History Pro forma Organic Growth of 10% in Surgical Products Segment for 2009 Supply and Reseller Agreement with Core Oncology adds to Momentum for 2010 BUFORD, Ga.-(BUSINESS WIRE)-February 11, 2010-Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical
February 8, 2010	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* THERAGENICS CORP (Name of Issuer) Common Stock (Title of Class of Securities) 883375107 (CUSIP Number) D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* THERAGENICS CORP (Name of Issuer) Common Stock (Title of Class of Securities) 883375107 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
December 3, 2009	EX-24	POWER OF ATTORNEY Power of Attorney for M Lang POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Francis J.
December 1, 2009	EX-24	POWER OF ATTORNEY Power of Attorney for M Lang POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lynn Rogers, Assistant Secretary of Theragenics Corporation® with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
November 13, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 4, 2009 or o TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 4, 2009 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORATION
November 12, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2009 (November 9, 20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2009 (November 9, 2009) THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission Fil
November 5, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: November 5, 2009 THERAGENICS CORPORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: November 5, 2009 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Brist
November 5, 2009	EX-99.1	Theragenics® Reports Revenue & Earnings for Third Quarter 2009 Highest Nine-Month Revenue Ever Continued Pro Forma Organic Growth in Surgical Products Business Exhibit 99.1 Theragenics? Reports Revenue & Earnings for Third Quarter 2009 Highest Nine-Month Revenue Ever Continued Pro Forma Organic Growth in Surgical Products Business BUFORD, Ga.-(BUSINESS WIRE)-November 5, 2009-Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for
August 28, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): (August 25, 2009) THERAGENICS COR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): (August 25, 2009) THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Empl
August 13, 2009	EX-10.1	AMENDED AND RESTATED CREDIT AGREEMENT DATED AS OF MAY 27, 2009 THERAGENICS CORPORATION, C.P. MEDICAL CORPORATION, GALT MEDICAL CORP. and NEEDLETECH PRODUCTS, INC., as Borrowers, WACHOVIA BANK, NATIONAL ASSOCIATION, as Bank Exhibit 10.1 AMENDED AND RESTATED CREDIT AGREEMENT DATED AS OF MAY 27, 2009 AMONG THERAGENICS CORPORATION, C.P. MEDICAL CORPORATION, GALT MEDICAL CORP. and NEEDLETECH PRODUCTS, INC., as Borrowers, and WACHOVIA BANK, NATIONAL ASSOCIATION, as Bank Article I 1 1. DEFINITIONS 1 1.1 Defined Terms 1 1.2 Accounting Terms 25 1.3 UCC Terms 25 1.4 Construction of Terms 25 1.5 Computation of Time Periods 26
August 13, 2009	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 5, 2009 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14339 THERAGENICS CORPORATION® (
August 6, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: August 6, 2009 THERAGENICS CORPORATIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: August 6, 2009 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 001-14339 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bristol
August 6, 2009	EX-99.1	Theragenics® Reports Revenue & Earnings for Second Quarter 2009 Second Consecutive Quarter of Record Revenue Exhibit 99.1 Theragenics® Reports Revenue & Earnings for Second Quarter 2009 Second Consecutive Quarter of Record Revenue BUFORD, Ga.-(BUSINESS WIRE)-August 6, 2009-Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended July 5, 2009. Consolidated r
July 22, 2009	CORRESP	July 22, 2009 July 22, 2009 Mr. Kevin L. Vaughn Accounting Branch Chief Division of Corporation Finance U.S. Securities and Exchange Commission 450 Fifth Street, N.W. Washington, DC 20549 Re: Theragenics Corporation Form 10-K for the Fiscal Year Ended December 31, 2008 Filed March 13, 2009 Form 8-K filed June 2, 2009 File No. 001-14339 Dear Mr. Vaughn: We offer the following information in response to the comme
June 25, 2009	CORRESP	June 25, 2009 June 25, 2009 Mr. Kevin L. Vaughn Accounting Branch Chief Division of Corporation Finance U.S. Securities and Exchange Commission 450 Fifth Street, N.W. Washington, DC 20549 Re: Theragenics Corporation Form 10-K for the Fiscal Year Ended December 31, 2008 Filed March 13, 2009 File No. 001-14339 Dear Mr. Vaughn: We offer the following information in response to the comments and questions raised in
June 2, 2009	EX-10.1	AMENDED AND RESTATED CREDIT AGREEMENT DATED AS OF MAY 27, 2009 THERAGENICS CORPORATION, C.P. MEDICAL CORPORATION, GALT MEDICAL CORP. and NEEDLETECH PRODUCTS, INC., as Borrowers, WACHOVIA BANK, NATIONAL ASSOCIATION, as Bank Exhibit 10.1 AMENDED AND RESTATED CREDIT AGREEMENT DATED AS OF MAY 27, 2009 AMONG THERAGENICS CORPORATION, C.P. MEDICAL CORPORATION, GALT MEDICAL CORP. and NEEDLETECH PRODUCTS, INC., as Borrowers, and WACHOVIA BANK, NATIONAL ASSOCIATION, as Bank Article I 1 1. DEFINITIONS 1 1.1 Defined Terms 1 1.2 Accounting Terms 25 1.3 UCC Terms 25 1.4 Construction of Terms 25 1.5 Computation of Time Periods 26
June 2, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): (May 27, 2009) THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-15443 58-1528626 (State of incorporation) (Commission File Number) (IRS Employe
May 20, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2009 THERAGENICS CORPORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2009 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-15443 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer
May 18, 2009	EX-24	POWER OF ATTORNEY Power of Attorney for Charles D. Moody, Jr. POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lynn Rogers, Assistant Secretary of Theragenics Corporation® with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Secur
May 18, 2009	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, Kathleen A. Dahlberg, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following o
May 18, 2009	EX-24	POWER OF ATTORNEY POA POWER OF ATTORNEY BE IT KNOWN, that I, John V. Herndon, the undersigned, do herby grant a power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: (1) Sign and file reports on Securities and Exchange Commission Forms 3,4,5 and 144 wi
May 18, 2009	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, K. Wyatt Engwall, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my
May 18, 2009	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, K. Wyatt Engwall, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my
May 18, 2009	EX-24	POWER OF ATTORNEY POA FOR PAAS POWER OF ATTORNEY BE IT KNOWN, that I, Peter A. A. Saunders, the undersigned, do herby grant a power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: (1) Sign and file reports on Securities and Exchange Commission Forms 3,
May 12, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 5, 2009 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-15443 THERAGENICS CORPORATION® (E
May 7, 2009	EX-99.1	Theragenics® Reports Revenue & Earnings for First Quarter 2009 $20.1 Million is Highest Revenue Quarter Ever Exhibit 99.1 Theragenics? Reports Revenue & Earnings for First Quarter 2009 $20.1 Million is Highest Revenue Quarter Ever BUFORD, Ga.-(BUSINESS WIRE)-May 7, 2009-Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended April 5, 2009. Consolidated resu
May 7, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: May 7, 2009 THERAGENICS CORPORATION® UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: May 7, 2009 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-15443 58-1528626 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 5203 Bristol In
April 6, 2009	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 23, 2009	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2009 THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-15443 58-1528626 (State of incorporation) (Commission File Number) (IRS Employe
March 18, 2009	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, Ronald Routhier, the undersigned, do herby grant a power of attorney to Francis J.
March 18, 2009	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, C. Russell Small, the undersigned, do herby grant a power of attorney to Francis J. Tarallo, Chief Fiancial Officer and Treasurer of Theragenics Corporation, and Lynn Rogers, Director of Treasury and Finance of Theragenics Corporation, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my
March 13, 2009	EX-10.36A	AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.36A AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) is dated December 31, 2008, between NeedleTech Products, Inc., a Massachusetts corporation (the “Company”), and Ronald Routhier (the “Employee”). INTRODUCTION The Company and the Employee are parties to that certain Employment Agreement dated July 28, 2008 (the “Employment Agreement”). The parties hereto now desire
March 13, 2009	EX-10.31A	AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.31A AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) is dated December 31, 2008, between Galt Medical Corp., a Delaware corporation (the “Company”), and Michael Lang (the “Employee”). INTRODUCTION The Company and the Employee are parties to that certain Employment Agreement dated August 21, 2007 (the “Employment Agreement”). The parties hereto now desire to amend the
March 13, 2009	EX-10.12F	AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.12F AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) is dated December 31, 2008, between Theragenics Corporation, a Delaware corporation (the “Company”), and Bruce W. Smith (the “Employee”). INTRODUCTION The Company and the Employee are parties to that certain Employment Agreement dated January 1, 1999, as amended (the “Employment Agreement”). The parties hereto now d
March 13, 2009	EX-10.13C	AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.13C AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) is dated December 31, 2008, between Theragenics Corporation, a Delaware corporation (the “Company”), and Michael O’Bannon (the “Employee”). INTRODUCTION The Company and the Employee are parties to that certain Employment Agreement dated January 1, 2000, as amended (the “Employment Agreement”). The parties hereto now
March 13, 2009	EX-10.11C	AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.11C AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (the “Amendment”) is dated December 31, 2008, between THERAGENICS CORPORATION, a Delaware corporation (the “Company”) and M. CHRISTINE JACOBS, an individual resident of Georgia (the “Executive”). INTRODUCTION: The Company and the Executive entered into that certain employment agreement dated April 13, 2000, as amended (the “Employment
March 13, 2009	EX-10.20A	AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.20A AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) is dated December 31, 2008, between Theragenics Corporation, a Delaware corporation (the “Company”), and Francis J. Tarallo (the “Employee”). INTRODUCTION The Company and the Employee are parties to that certain Employment Agreement dated August 10, 2005 (the “Employment Agreement”). The parties hereto now desire to
March 13, 2009	EX-21.1	SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT CP Medical Corporation, a Delaware corporation Galt Medical Corp., a Texas corporation NeedleTech Products, Inc., a Massachusetts corporation
March 13, 2009	EX-10.37A	AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.37A AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) is dated December 31, 2008, between NeedleTech Products, Inc., a Massachusetts corporation (the “Company”), and Russell Small (the “Employee”). INTRODUCTION The Company and the Employee are parties to that certain Employment Agreement dated July 28, 2008 (the “Employment Agreement”). The parties hereto now desire to
March 13, 2009	EX-10.40	STANDARD FORM COMMERCE LEASE Exhibit 10.40 STANDARD FORM COMMERCE LEASE 1. PARTIES (fill in) LESSOR, which expression shall include its heirs, successors, and assigns where the context so admits, does hereby lease to NEEDLETECH PRODUCTS, INC., a Massachusetts corporation with a regular place of business at 81 West Street, Attleboro, MA 02703 2. PREMISES (fill in and include, if ap-plicable, suite number, floor LESSEE, which e
March 13, 2009	EX-10.21A	AMENDMENT TO PERFORMANCE RESTRICTED STOCK RIGHTS AGREEMENT PURSUANT TO THERAGENICS CORPORATION 2000 STOCK INCENTIVE PLAN Exhibit 10.21A AMENDMENT TO PERFORMANCE RESTRICTED STOCK RIGHTS AGREEMENT PURSUANT TO THERAGENICS CORPORATION 2000 STOCK INCENTIVE PLAN THIS AMENDMENT (this “Amendment”) is made on December , 2008, by THERAGENICS CORPORATION, a Delaware corporation (the “Company”) and (the “Recipient”). INTRODUCTION: The Company previously granted to the Recipient on February , 2006, Performance Restricted Stock R
March 13, 2009	EX-10.38A	AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.38A AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (this “Amendment”) is dated December 31, 2008, between CP Medical Corp., an Oregon corporation (the “Company”), and Janet Zeman (the “Employee”). INTRODUCTION The Company and the Employee are parties to that certain Employment Agreement dated August 6, 2008 (the “Employment Agreement”). The parties hereto now desire to amend the Emplo
March 13, 2009	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2008 o TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 0-15443 THERAGENICS CORPORATION® (Exact
March 10, 2009	EX-24	POWER OF ATTORNEY Power of Attorney for Charles D. Moody, Jr. POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lynn Rogers, Assistant Secretary of Theragenics Corporation® with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Secur
March 5, 2009	EX-24	POWER OF ATTORNEY POA POWER OF ATTORNEY BE IT KNOWN, that I, John V. Herndon, the undersigned, do herby grant a power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: (1) Sign and file reports on Securities and Exchange Commission Forms 3,4,5 and 144 wi
March 5, 2009	EX-24	LIMITED POWER OF ATTORNEY poa LIMITED POWER OF ATTORNEY BE IT KNOWN, that I, Bruce W. Smith, the undersigned, do hereby grant a limited power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact. My attorney-in-fact shall have the full power and authority to undertake and perform the following on my behalf: 1. Sign and file reports on Securities and Exchange Commission Forms 3
March 4, 2009	EX-10.1	THERAGENICS CORPORATION 2009 LONG-TERM CASH INCENTIVE PLAN SECTION I. INTRODUCTION Exhibit 10.1 THERAGENICS CORPORATION 2009 LONG-TERM CASH INCENTIVE PLAN SECTION I. INTRODUCTION 1.1 Purpose. The purpose of the Theragenics Corporation 2009 Long-Term Cash Incentive Plan (the “Plan”) set forth below is to provide cash incentive compensation to certain employees of Theragenics Corporation (the “Company”) and its affiliates to stimulate their efforts to attain certain cumulative rev
March 4, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2009 (February 26, 2009) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2009 (February 26, 2009) THERAGENICS CORPORATION® (Exact name of registrant as specified in charter) Delaware 000-15443 58-1528626 (State of incorporation) (Commission File N
March 2, 2009	EX-24	LIMITED POWER OF ATTORNEY obannon poa LIMITED POWER OF ATTORNEY BE IT KNOWN, that I, Michael O’Bannon, the undersigned, do hereby grant a limited power of attorney to Lynn Rogers, Assistant Secretary of Theragenics Corporation®, as my attorney-in-fact.
March 2, 2009	EX-24	POWER OF ATTORNEY Power of Attorney for Frank Tarallo POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lynn Rogers, Assistant Secretary of Theragenics Corporation® with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.
March 2, 2009	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY IT KNOWN, that I, Janet Zeman, the undersigned, do herby grant a power of attorney to Francis J.

TGX / Theragenics Corp - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)